Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol. 1991

K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
First Department of Surgery, Kyoto Prefectural University of Medicine.

The murine monoclonal antibody A7 (Mab A7) was chemically modified with several macromolecules: dextran, polyethylene glycol and the anti-cancer polypeptide neocarzinostatin. The pharmacokinetic properties of the combinations were subsequently examined. Radioimmunoassay revealed that all preparations retained their antigen-binding activities. The Mab A7-neocarzinostatin conjugate was cleared from the blood circulation with a kinetic pattern almost identical to that of the parent Mab A7. Of the three preparations, Mab A7-dextran (A7-Dx) was removed the most rapidly from the circulation. Mab A7-polyethylene glycol (A7-PEG) exhibited the slowest blood clearance curve, with twice the half life of the parent Mab A7 in the circulation. In normal organ distributions, A7-Dx exhibited the highest liver, spleen and kidney uptake, and A7-PEG showed the lowest uptake, when expressed as tissue:blood ratio. Although A7-Dx exhibited lower tumor uptake, there was no significant difference among the three conjugates in tumor-bearing nude mice. A7-PEG seems to be a good candidate for targeted cancer therapy using antibody due to its high blood retention but low normal organ uptake.

UI MeSH Term Description Entries
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009353 Zinostatin An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic. Neocarzinostatin
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
September 2013, Journal of biomedical materials research. Part A,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
April 1990, Gastroenterologia Japonica,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
January 2019, Colloids and surfaces. B, Biointerfaces,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
February 1982, Pharmacological research communications,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
August 1993, Journal of surgical oncology,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
December 2000, Chemical & pharmaceutical bulletin,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
February 1994, Japanese journal of cancer research : Gann,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
December 2010, Colloids and surfaces. B, Biointerfaces,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
July 1990, Chemical & pharmaceutical bulletin,
K Takashina, and K Kitamura, and T Yamaguchi, and A Noguchi, and A Noguchi, and H Tsurumi, and T Takahashi
June 1996, British journal of cancer,
Copied contents to your clipboard!